Showing results (71-80 of 280) with videos related to
Sort By:
Pageof 28
Journal of Managed Care & Specialty Pharmacy|July 1, 2024
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.Journal of Oncology Practice|September 3, 2015
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World PracticeAaron P Mitchell, Michael R Harrison, Mark S Walker, et al.Journal for Immunotherapy of Cancer|January 26, 2018
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyondJason Zhu, Andrew J Armstrong, Terence W Friedlander, et al.JAMA Network Open|August 27, 2024
Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate CancerDaniel J George, Alicia K Morgans, Niculae Constantinovici, et al.Prostate Cancer and Prostatic Diseases|March 19, 2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT studyNeal D Shore, Daniel J George, Nasreen Khan, et al.Clinical Genitourinary Cancer|September 19, 2015
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate CancerMichaela A Dinan, Yanhong Li, Yinghong Zhang, et al.Prostate Cancer and Prostatic Diseases|November 4, 2021
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancerDaniel J George, Krishnan Ramaswamy, Ahong Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George, Susan Halabi, Timothy F Shepard, et al.Clinical Genitourinary Cancer|February 26, 2023
Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate CancerStephen J Freedland, Krishnan Ramaswamy, Ahong Huang, et al.Clinical Prostate Cancer|July 29, 2004
Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancerMiyako Abe, Judith B Manola, William K Oh, et al.Pageof 28